Study Summary
This trial will study a new drug to see if it is safe & effective to treat advanced cancers. Up to 240 people will take part.
- Solid Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 9 Secondary · Reporting Duration: From baseline to the end of study (up to 2 years)
Trial Safety
Safety Progress
Trial Design
5 Treatment Groups
SAR445877 Escalation Phase (Part 1)
1 of 5
SAR445877 Expansion Phase: Cohort A (Part 2)
1 of 5
SAR445877 Expansion Phase: Cohort B (Part 2)
1 of 5
SAR445877 Expansion Phase: Cohort C (Part 2)
1 of 5
SAR445877 Expansion Phase: Cohort D (Part 2)
1 of 5
Experimental Treatment
240 Total Participants · 5 Treatment Groups
Primary Treatment: SAR445877 Escalation Phase (Part 1) · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Might an individual be able to participate in this clinical research endeavor?
"The trial is presently enrolling patients, according to clinicaltrials.gov reports. It was initially launched on the 29th of November 2022 and updated most recently on December 8th 2022." - Anonymous Online Contributor
What is the aggregate number of participants enrolled in this experiment?
"Confirmed. According to clinicaltrials.gov, this medical trial that first appeared on November 29th 2022 is presently recruiting participants. 240 candidates will be accepted from a single location for this investigation." - Anonymous Online Contributor
What objectives are researchers hoping to accomplish with this research initiative?
"The primary outcome of this investigation, which will be surveyed from the start to two years after dose expansion, is to assess any presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2. Secondary metrics that shall be assessed include incidences of anti-drug antibodies (ADAs), SAR445877 area under the concentration versus time curve calculated during a dosing interval (T), as well as adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 or American Society for Transplantation and Cellular Therapy consensus grading." - Anonymous Online Contributor